CY1123769T1 - Νουκλεϊκα οξεα για την αγωγη αλλεργιων - Google Patents

Νουκλεϊκα οξεα για την αγωγη αλλεργιων

Info

Publication number
CY1123769T1
CY1123769T1 CY20201101107T CY201101107T CY1123769T1 CY 1123769 T1 CY1123769 T1 CY 1123769T1 CY 20201101107 T CY20201101107 T CY 20201101107T CY 201101107 T CY201101107 T CY 201101107T CY 1123769 T1 CY1123769 T1 CY 1123769T1
Authority
CY
Cyprus
Prior art keywords
vaccines
nucleic acids
protein
lamp
allergenic
Prior art date
Application number
CY20201101107T
Other languages
English (en)
Inventor
William Hearl
Teri Heiland
Original Assignee
Immunomic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics, Inc. filed Critical Immunomic Therapeutics, Inc.
Publication of CY1123769T1 publication Critical patent/CY1123769T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει DNA εμβόλια για την αγωγή αλλεργιών. Τα εμβόλια περιλαμβάνουν την κωδικεύουσα αλληλουχία για έναν ή περισσότερους αλλεργιογόνους επίτοπους, και κατά προτίμηση για την πλήρη πρωτεϊνοαλληλουχία, της αλλεργιογονικής πρωτεΐνης από την οποία προέρχεται(ονται) ο(ι) επίτοπος(οι), συντηγμένη εντός πλαισίου με την αυλική επικράτεια της συνδεόμενης με το λυσόσωμα μεμβρανοπρωτεΐνη (LAMP) και την αλληλουχία στόχευσης της LAMP. Τα εμβόλια επιτρέπουν παρουσίαση τρισδιάστατων επίτοπων, κατάλληλα διαμορφωμένων, για την παραγωγή ανοσοαπόκρισης. Τα εμβόλια μπορούν να σχεδιαστούν να είναι πολυσθενή μόρια, και/ή μπορούν να παρασχεθούν ως μέρος ενός πολυσθενούς εμβολίου περιέχοντος δύο και άνω DNA δομήματα.
CY20201101107T 2012-06-15 2020-11-23 Νουκλεϊκα οξεα για την αγωγη αλλεργιων CY1123769T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (1)

Publication Number Publication Date
CY1123769T1 true CY1123769T1 (el) 2022-05-27

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101107T CY1123769T1 (el) 2012-06-15 2020-11-23 Νουκλεϊκα οξεα για την αγωγη αλλεργιων

Country Status (20)

Country Link
US (3) US9744230B2 (el)
EP (2) EP3808361A1 (el)
JP (1) JP5807994B2 (el)
KR (2) KR102107646B1 (el)
CN (2) CN104519896B (el)
AU (3) AU2012382406B2 (el)
BR (1) BR112014031327B1 (el)
CA (1) CA2876824C (el)
CY (1) CY1123769T1 (el)
DK (1) DK2861240T3 (el)
ES (1) ES2831723T3 (el)
HR (1) HRP20201815T1 (el)
HU (1) HUE052481T2 (el)
IL (4) IL236174B (el)
LT (1) LT2861240T (el)
PL (1) PL2861240T3 (el)
PT (1) PT2861240T (el)
RS (1) RS61098B1 (el)
SI (1) SI2861240T1 (el)
WO (1) WO2013187906A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
HUE052481T2 (hu) 2012-06-15 2021-04-28 Immunomic Therapeutics Inc Nukleinsavak, allergiák kezelésére
MX2015005636A (es) 2012-10-30 2015-11-16 Univ Monash Moléculas inmunoterapéuticas novedosas y sus usos.
KR20160075532A (ko) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CN106459994A (zh) * 2014-06-23 2017-02-22 免疫治疗有限公司 用于治疗花生过敏的核酸
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
KR102319839B1 (ko) 2015-12-23 2021-11-01 메디진 이뮤노테라피스 게엠바하 항원-특이적 tcr의 신규 생성
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
US11203629B2 (en) * 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
AU2018263923A1 (en) * 2017-05-02 2019-10-31 Immunomic Therapeutics, Inc. LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
WO2019194656A1 (ko) * 2018-04-06 2019-10-10 (주)에스엘에스바이오 신규한 면역글로불린 e의 에피토프, 그와 결합하는 항체 및 상기 항체를 포함하는 시료 중 면역글로불린 e를 분석하기 위한 키트
CN112105735A (zh) * 2018-05-11 2020-12-18 安斯泰来制药株式会社 用于螨过敏治疗的核酸
EP3792361A4 (en) * 2018-05-11 2022-01-26 Astellas Pharma Inc. NUCLEIC ACID FOR TREATMENT OF CRUSTACEANS ALLERGY
WO2019222281A1 (en) * 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
US11766477B2 (en) 2019-01-23 2023-09-26 Societe Des Produits Nestle S.A. Methods for making mixed allergen compositions
US20220233686A1 (en) * 2019-03-13 2022-07-28 Psomagen Inc. Epitope-Based Approach for Allergy Treatments and Inhibitors for Crohn's Disease
WO2023013787A1 (ja) * 2021-08-06 2023-02-09 花王株式会社 Ｓｎａｒｅを活用した核酸構築物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH08505284A (ja) * 1992-11-12 1996-06-11 イミュロジック ファーマスーティカル コーポレイション 杉花粉由来のアレルゲン性蛋白質及びペプチド
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
CA2241918C (en) 1995-12-29 2008-12-02 University Of Arkansas Peanut allergens and methods
DE69737659T2 (de) 1996-06-14 2007-12-27 Meiji Dairies Corp. Peptide aus t-zellepitopen
AU2001251407A1 (en) * 2000-04-07 2001-10-23 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
US8318173B2 (en) * 2001-04-05 2012-11-27 The John Hopkins University Chimeric vaccines
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
WO2006138435A2 (en) 2005-06-16 2006-12-28 Mount Sinai School Of Medicine Methods for enhancing immune responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1932538A4 (en) * 2005-08-25 2009-10-21 Taiho Pharmaceutical Co Ltd BIODEGRADABLE NANOTEHICLES WITH IMMOBILIZED OR CAPACITATED T-CELL-RECOGNIZABLE EPITOPEPEPID
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
EP2331568B1 (en) * 2008-09-10 2014-09-03 ITH Immune Therapy Holdings AB Treating inflammatory conditions
HUE052481T2 (hu) 2012-06-15 2021-04-28 Immunomic Therapeutics Inc Nukleinsavak, allergiák kezelésére

Also Published As

Publication number Publication date
IL270262A (en) 2019-12-31
CN104519896A (zh) 2015-04-15
SI2861240T1 (sl) 2021-04-30
IL270260B (en) 2020-08-31
JP2015521467A (ja) 2015-07-30
AU2018200625A1 (en) 2018-02-15
HUE052481T2 (hu) 2021-04-28
EP3808361A1 (en) 2021-04-21
KR102386481B1 (ko) 2022-04-14
AU2012382406A2 (en) 2015-04-16
EP2861240B1 (en) 2020-09-09
WO2013187906A1 (en) 2013-12-19
AU2018200625B2 (en) 2019-09-19
AU2019250227A1 (en) 2019-11-07
BR112014031327B1 (pt) 2022-02-01
US20160271245A1 (en) 2016-09-22
RS61098B1 (sr) 2020-12-31
KR20150032286A (ko) 2015-03-25
KR102107646B1 (ko) 2020-05-08
CN104519896B (zh) 2017-11-10
AU2019250227B2 (en) 2021-10-21
BR112014031327A2 (pt) 2017-06-27
PL2861240T3 (pl) 2021-07-05
EP2861240A4 (en) 2016-03-16
IL270261B (en) 2021-03-25
PT2861240T (pt) 2020-11-09
US10072053B2 (en) 2018-09-11
AU2012382406B2 (en) 2017-12-07
ES2831723T3 (es) 2021-06-09
CA2876824C (en) 2020-07-21
US20220081474A1 (en) 2022-03-17
JP5807994B2 (ja) 2015-11-10
US9744230B2 (en) 2017-08-29
CN107937423A (zh) 2018-04-20
CA2876824A1 (en) 2013-12-19
LT2861240T (lt) 2021-01-25
EP2861240A1 (en) 2015-04-22
IL236174A0 (en) 2015-01-29
US20180009857A1 (en) 2018-01-11
KR20200047792A (ko) 2020-05-07
AU2012382406A1 (en) 2014-12-18
IL236174B (en) 2019-11-28
DK2861240T3 (da) 2020-09-28
HRP20201815T1 (hr) 2021-02-19

Similar Documents

Publication Publication Date Title
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
WO2015200357A3 (en) Nucleic acids for treatment of peanut allergies
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
CY1122035T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
CY1121934T1 (el) Αντισωματα anti-fcrn
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
CY1124979T1 (el) Κατασκευασματα πρωτεϊνης uspa2 και χρησεις αυτων
WO2018093932A3 (en) Nucleic acids for treatment of allergies
CY1110178T1 (el) Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ι ή ιι για εμβολια
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
EA201391597A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
EA202090759A2 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
MX2017015404A (es) Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
MX337202B (es) Vacunas de conjugado carbohidrato-glicolipido.
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
CY1124685T1 (el) Εξατομικευμενα εμβολια για τον καρκινο
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων